Laura Chico

Biogen Inc (NASDAQ:BIIB) reported better-than-expected fourth-quarter results, prompting analysts to share insights on the company’s trajectory. Wedbush analyst Laura Chico maintained a Neutral rating, while lifting the price target from $178 to $187. HC Wainwright analyst Andrew Fein...

Circle March 20 on your calendars! Starting at 10:25 a.m. EST Wednesday, the Benzinga Virtual Healthcare Summit 2024 is the place to be. Imagine a digital room buzzing with the likes of Beachbody’s Mark Goldston, Autonomix Medical’s Lori Bisson, and IGC Pharma’s Ram Mukunda (NYSE:...

For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the S&P 500 index, Wedbush's Laura Chico said Wednesday on "PreMarket Prep Plus." Chico, the senior vice president of biotech equity research at the analyst firm, said she...

Prevail Therapeutics Inc (NASDAQ: PRVL) shares traded higher on Monday after a pair of Wall Street analyst initiated bullish coverage of the stock. The Analyst Bank of America analyst Tazeen Ahmad initiated coverage of Prevail with a Buy rating and $15 price target. The Thesis Ahmad said Prevail...

Wedbush's meetings with Acer Therapeutics Inc (NASDAQ: ACER) in the wake of last week's 14-percent decline in the stock suggest that the review of ast week’s 14 percent decline in the company’s share price, suggest the review of the company's Edsivo product is on track...

Acorda Therapeutics Inc (NASDAQ: ACOR) announced FDA approval for its Parkinson's drug Inbrija Monday, boosting the stock in premarket trading. Not everyone is sold on the product’s prospects. The Analyst  Raymond James analyst Laura Chico maintained an Underperform rating on the...

Raymond James launched coverage of two pharmaceutical names Tuesday afternoon with bullish ratings. Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) is a clinical-stage biopharmaceutical company that addresses key mechanisms of tumor drug resistance. Dova Pharmaceuticals Inc (NASDAQ: DOVA)...

Biogen Inc (NASDAQ: BIIB) and its Japanese partner Eisai disclosed encouraging results from an 18-month Phase 2 study of its Alzheimer's therapy BAN2401. Here's how some Street analysts reacted to the news.  The Analysts Raymond James' Laura Chico maintained a Market...